Oct 10, 2018 Long-Term Ocrelizumab Reduces Relapse Rate and Disability Progression in MS Long-Term Ocrelizumab Reduces Relapse Rate and Disability Progression in MSPatients with multiple sclerosis who initiated ocrelizumab therapy earlier and continued long-term treatment sustained lower annualized relapse rates ... read morePublished on 2018-10-10